59,200 Shares in Palvella Therapeutics, Inc. $PVLA Bought by Artia Global Partners LP

Artia Global Partners LP bought a new position in shares of Palvella Therapeutics, Inc. (NASDAQ:PVLA) in the 4th quarter, Holdings Channel.com reports. The institutional investor bought 59,200 shares of the company’s stock, valued at approximately $6,196,000. Palvella Therapeutics accounts for about 0.9% of Artia Global Partners LP’s portfolio, making the stock its 20th largest holding.

Several other large investors have also added to or reduced their stakes in PVLA. First Light Asset Management LLC acquired a new position in Palvella Therapeutics during the third quarter worth $33,949,000. Summit Partners Public Asset Management LLC boosted its holdings in Palvella Therapeutics by 1,016.0% during the fourth quarter. Summit Partners Public Asset Management LLC now owns 389,420 shares of the company’s stock worth $40,761,000 after purchasing an additional 354,525 shares during the last quarter. Vanguard Group Inc. boosted its holdings in Palvella Therapeutics by 202.0% during the third quarter. Vanguard Group Inc. now owns 494,656 shares of the company’s stock worth $31,010,000 after purchasing an additional 330,847 shares during the last quarter. State Street Corp boosted its holdings in Palvella Therapeutics by 206.3% during the fourth quarter. State Street Corp now owns 420,462 shares of the company’s stock worth $44,010,000 after purchasing an additional 283,211 shares during the last quarter. Finally, Jennison Associates LLC boosted its holdings in Palvella Therapeutics by 262.4% during the fourth quarter. Jennison Associates LLC now owns 387,483 shares of the company’s stock worth $40,558,000 after purchasing an additional 280,573 shares during the last quarter. Institutional investors and hedge funds own 40.11% of the company’s stock.

Palvella Therapeutics Stock Performance

NASDAQ PVLA opened at $112.63 on Thursday. The firm has a 50-day moving average of $118.97 and a 200-day moving average of $108.85. The stock has a market cap of $1.62 billion, a PE ratio of -27.01 and a beta of -0.15. Palvella Therapeutics, Inc. has a 52-week low of $20.20 and a 52-week high of $151.18.

Palvella Therapeutics (NASDAQ:PVLA) last posted its earnings results on Thursday, May 7th. The company reported ($1.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.30). As a group, analysts predict that Palvella Therapeutics, Inc. will post -5.26 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have commented on PVLA shares. Stifel Nicolaus set a $250.00 price target on shares of Palvella Therapeutics in a research note on Tuesday, February 24th. Stephens reiterated an “overweight” rating and issued a $220.00 price target on shares of Palvella Therapeutics in a research note on Thursday, May 21st. Truist Financial set a $210.00 price target on shares of Palvella Therapeutics in a research note on Tuesday, February 24th. Chardan Capital reiterated a “buy” rating and issued a $240.00 price target on shares of Palvella Therapeutics in a research note on Thursday, May 21st. Finally, HC Wainwright increased their price target on shares of Palvella Therapeutics from $255.00 to $270.00 and gave the company a “buy” rating in a research note on Tuesday, March 24th. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Palvella Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $199.53.

Palvella Therapeutics Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.